GlassScriptPhysician profile
Stephen L Adams
NPI 1740486646
$1,558.48
in general payments reported to CMS, 2019-2025
22 companies · $95.00 in 2025
The $95.00 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $198 · 2021: $231 · 2022: $205 · 2023: $353 · 2024: $317 · 2025: $95.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $764.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $344.41 | 2021-2025 | Ubrelvy, Qulipta |
| Astellas Pharma US INC | $238.56 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $124.24 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $109.91 | 2020-2021 | |
| Lilly USA, LLC | $97.18 | 2019-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $89.16 | 2019-2024 | Airsupra |
| Sunovion Pharmaceuticals INC. | $87.80 | 2019-2020 | |
| Allergan, INC. | $64.69 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.42 | 2022-2024 | |
| Philips North America LLC | $49.02 | 2023-2024 | (Ck4) Mcot |
| Glaxosmithkline, LLC. | $44.14 | 2022-2023 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $39.24 | 2022 | |
| Exact Sciences Corporation | $38.82 | 2023-2024 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $34.07 | 2021-2022 | |
| Convatec INC. | $29.93 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $18.60 | 2021 | |
| Merck Sharp & Dohme LLC | $17.91 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.20 | 2021 | |
| Teleflex LLC | $16.20 | 2021 | |
| Novo Nordisk INC | $15.97 | 2025 | Ozempic |
| Sanofi Pasteur INC. | $14.77 | 2019 | |
| Pacira Therapeutics, INC. | $13.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.